Questions have been raised about potentially negative effects of antenatal folic acid use in populations with a high prevalence of vitamin B-12 deficiency. Our objective was to examine the association between maternal folate and vitamin B-12 status in pregnancy on offspring insulin resistance and examine whether the effects of maternal micronutrient supplementation varied by baseline maternal folate and/or vitamin B-12 status. Pregnant women were cluster randomized to receive daily supplements containing vitamin A alone or with folic acid, folic acid+iron, folic acid+iron+zinc, or a multiple micronutrient. In a subsample (n = 1132), micronutrient status biomarkers were analyzed at baseline and late pregnancy.
Introduction
Questions have been raised that prenatal folic acid supplementation to women who are vitamin B-12 deficient might have long-term negative effects on the health of the offspring (1) (2) (3) . This arose out of a finding from an observational study in Pune, India that reported that 6-to 7-y-old children whose mothers had either low vitamin B-12 status at 18 wk of gestation or high erythrocyte folate status at 28 wk of gestation had an elevated risk of insulin resistance, with the highest levels of insulin resistance occurring in children whose mothers had both high folate and low vitamin B-12 status during pregnancy (1) .
There are limited data on the global prevalence of vitamin B-12 deficiency (4), but it is thought to be common in much of South Asia, particularly among those consuming a vegetarian diet. For example, in Sarlahi District of Nepal, 28% of pregnant women had a low serum vitamin B-12 (,150 pmol/L) status in early pregnancy (5) . In Pune, India, 60% of women had low vitamin B-12 status and 94% had elevated methylmalonic acid (.0.26 mmol/L) at 18 wk of gestation (1) . In these 2 studies, folate deficiency was less common: 11% of women in Sarlahi had low plasma folate (,6.7 nmol/L), whereas only one woman in the Pune study had low erythrocyte folate (,283 nmol/L). In adults, low vitamin B-12 status is associated with anemia, neuropathy, and cognitive impairment (6) . Infant vitamin B-12 status also has been shown to be correlated with that of the mother (7) , which, when deficient, has been associated with early pregnancy loss (8) and impaired neurodevelopment in infants (9) . Low folate status in early pregnancy is an established risk factor for neural tube defects (10) . Currently, in many countries where iron deficiency anemia is common, iron and folic acid supplements are recommended for women during pregnancy, although coverage remains low (11) .
We conducted a cluster-randomized, controlled trial of supplementation with different combinations of micronutrients among women during pregnancy and postpartum in rural Nepal and conducted biochemical assessments of micronutrient status in a subsample at baseline and late pregnancy (5, 12, 13) . In a longitudinal follow-up study, we visited the children born to women in the trial when they were 6-8 y of age and measured their fasting glucose and insulin levels as well as other outcomes. We found no overall effect of maternal micronutrient supplementation on offspring plasma glucose, insulin, or hemoglobin A1c, or insulin resistance as indicated by the homeostasis model of insulin resistance (HOMA-IR), although folic acid alone reduced the risk of metabolic syndrome by 37% (14) . In this analysis, we examined whether maternal folate or vitamin B-12 status predicts offspring insulin resistance and whether it modifies the effect of supplementation with folic acid alone or in combination with iron, zinc, and other micronutrients including vitamin B-12 on the risk of insulin resistance in the offspring. This analysis specifically addresses the issue of whether gestational folic acid supplementation among vitamin B-12-deficient women increases the risk of insulin resistance among children.
Methods
From 1999-2001, we conducted a cluster-randomized, controlled trial of antenatal micronutrient supplements in the rural District of Sarlahi in Nepal, the methods of which have been previously described (13) . In brief, a total of 4998 women were enrolled in early pregnancy and allocated to 1 of 5 supplement groups: 1) a control; 2) folic acid (400 mg); 3) folic acid+iron (60 mg ferrous fumarate); 4) folic acid+iron+zinc (30 mg zinc sulfate); or 5) multiple micronutrients containing folic acid, iron, zinc, and an additional 11 vitamins and minerals (10 mg vitamin D as cholecalciferol, 10 mg vitamin E as d-a tocopherol, 1.6 mg thiamine, 1.8 mg riboflavin, 20 mg niacin, 2.2 mg vitamin B-6, 2.6 mg vitamin B-12, 100 mg vitamin C, 65 mg vitamin K as phylloquinone, 2.0 mg Cu, 100 mg Mg). All supplements were given with 1000 mg RE of preformed vitamin A (retinyl palmitate) and compared to vitamin A alone as control. A household socioeconomic status interview was conducted at baseline.
Of the 30 village development communities that were included in the main trial, 9 were selected for ease of access to clinic sites and to obtain balanced geographic and ethnic representation for inclusion in a subsample of women for more intensive study. Women residing in these communities were invited to participate in an enhanced series of assessments, including a blood draw at baseline and in late pregnancy for the assessment of micronutrient status. The mean (6 SD) gestational age at participation in early pregnancy was 10.2 6 4.1 wk and in late pregnancy was 32.6 6 3.9 wk. Detailed methods and results were previously published (5) . A total of 1316 women were eligible for inclusion in the substudy and 1165 agreed to provide a blood sample. From 2006 to 2008, the surviving children born during the trial were revisited and assessed during a series of household visits, the methods of which have been described elsewhere (14, 15) . Children were asked to fast overnight and a team of phlebotomists traveled to the households early in the morning to collect blood and urine specimens.
The methods for the micronutrient status assessment were previously described in detail (5) . In the maternal samples, plasma folate was measured with a microbiological assay using a chloramphenicol-resistant strain of Lactobacillus rhamnosus (NCIMB 10463) (16) . Serum vitamin B-12 was measured by a microbiological assay using a colostin-sulfateresistant strain of Lactobacillus lactis (NCIMB 12519) (17, 18) . Homocysteine was analyzed with a microtiter plate assay (Calbiotech), which is similar to an enzyme immunoassay and uses genetically engineered homocysteine-binding protein as the capturing agent (5).
In the child samples, plasma glucose was measured using a Cholestech LDX analyzer with standard test kits (Cholestech). Plasma insulin was measured using an ultrasensitive sandwich immunoassay (Alpco Diagnostics). The HOMA-IR was calculated using the standard ratio formula: HOMA-IR = (FPI 3 FPG)/22.5, where FPI is fasting plasma insulin (pmol/L) and FPG is fasting plasma glucose (mmol/L) (19) . Blood samples were collected from all assenting children; however, 30% had not fasted on the morning of the blood draw. For these children, insulin and glucose measures were not reported.
Plasma folate, vitamin B-12, glucose, insulin, and HOMA-IR all had a skewed distribution and are reported with medians and interquartile ranges and were log transformed for analysis. Low vitamin B-12 status during pregnancy was defined as ,148 pmol/L (20) . For this analysis, low folate was defined as a plasma folate concentration less than the median value (14.2 nmol/L), because at baseline only 11% of women were folate deficient (,6.8 nmol/L) (20) and 3% of women had high folate concentrations ($45.3 nmol/L) (21) . Children were included in this analysis if they had complete data on insulin and glucose at follow-up and if there was folate or vitamin B-12 data from at least one time point in pregnancy in their mothers.
The association between maternal folate and vitamin B-12 status during early and late pregnancy and child HOMA-IR was assessed using linear regression models. Household SES factors, ethnicity, paternal occupation, maternal literacy, maternal age at enrollment in the trial, BMI at baseline, parity, height, smoking and alcohol consumption during pregnancy, birth weight, and child age and gender were considered as potential confounding variables. Covariates were chosen for inclusion in the final model if they were significant in bivariate associations (P , 0.05) with either baseline folate or vitamin B-12 status or offspring HOMA and remained significant in multivariate models. The percent difference in HOMA-IR was also calculated stratified on maternal baseline folate or vitamin B-12 status categorized as deficient and nondeficient. To examine the interaction between baseline folate and vitamin B-12 status and micronutrient supplementation on child HOMA-IR, generalized estimation equations were used to account for the clusterrandomized study design. The interaction between treatment group and baseline folate or vitamin B-12 status was tested by including an interaction term into the model and testing its significance. P , 0.1 was considered significant for interactions. Analyses were performed using Stata SE v. 11. The follow-up study received ethical approval from the institutional review boards at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD) and the Institute of Medicine in Nepal.
Results
Of the 1132 mothers and 1143 children (22 of whom were twins) originally included in the laboratory subsample, 891 children (78%) were successfully contacted to provide a blood sample at the follow-up visit. Of these, data on folate and vitamin B-12 status were available for 810 women during pregnancy and complete data on fasting glucose and insulin were available for 598 children. Most of the missing child data were due to the fact that 285 children were not fasting on the morning of the blood draw. Thus, data on the biomarkers of interest were complete for a total of 545 mother-child pairs.
The pregnancy and birth characteristics of the selected sample are shown in Table 1 . Nearly all women had normal or low BMI during pregnancy and the children had a mean BMI for age Z-score that was , 21. Vitamin B-12 deficiency was relatively common, affecting nearly 30% of mothers, but folate deficiency was relatively uncommon.
When examined using continuous models, neither folate nor vitamin B-12 status was significantly associated with child HOMA-IR in either early or late pregnancy ( Table 2) . Including both folate and vitamin B-12 status in the model together did not affect the point estimates or CI. The change in folate or vitamin B-12 status over pregnancy was also examined and not found to be significantly associated with child HOMA-IR either alone or when included together in models with baseline status (data not shown). However, when examined using a cutoff of ,148 pmol/L, maternal low vitamin B-12 status at baseline was associated with a 26.7% increase in HOMA-IR (95% CI: 3.5-55.1%; P = 0.02) (Fig. 1) compared to children whose mothers had a higher vitamin B-12 status at baseline after adjustment for potential confounding variables, including child age, gender, ethnicity, maternal height and literacy, and household radio ownership. Low vitamin B-12 status in late pregnancy was not associated with offspring HOMA-IR (4.1, 216.7-29.9%; P = 0.726) after adjustment. There was no association between low maternal folate status (,14.2 nmol/L) during early pregnancy (211.3, 227.7-8.6%) or late pregnancy (3.6, 15.9-27.7%) and offspring HOMA-IR after adjustment.
There was some evidence that the effect of the maternal micronutrient interventions on child HOMA-IR varied by folate or vitamin B-12 status in early pregnancy, although results were inconsistent ( Table 3 ). Children whose mothers had a high vitamin B-12 status in early pregnancy and who received folic acid+iron or the multiple micronutrient supplement had a significant increase in HOMA-IR relative to controls. However, children whose mothers received folic acid alone or in combination with iron and zinc did not show the same relationship. There was no evidence of an effect of any of the interventions among children whose mothers had a low vitamin B-12 status. There were also no significant interactions between maternal vitamin B-12 status and intervention group on child HOMA-IR (P . 0.1 for all). When stratified on maternal folate status, the folic acid+iron supplementation group had significantly higher HOMA-IR among children born to women with lower folate status at baseline. There were no significant effects among children born to women who had higher folate status and none of the interaction terms were significant (P . 0.1 for all).
Discussion
We report here the associations between maternal folate and vitamin B-12 status during pregnancy on markers of child insulin resistance and whether the effect of maternal micronutrient supplementation during pregnancy differed based on maternal status at baseline. Although there was not a linear association between maternal vitamin B-12 status during pregnancy and child HOMA-IR, we found evidence that maternal low plasma vitamin B-12 status in early pregnancy was associated with a significant elevation in child HOMA-IR. This association was not apparent in relation to late pregnancy vitamin B-12 status. We also found no association with maternal folate status at either measurement point and offspring insulin resistance, nor did we see evidence of an interaction between maternal folate or vitamin B-12 status at either time during pregnancy and offspring insulin resistance. Among children whose mothers were not vitamin B-12 deficient or who had lower folate status at baseline and who received folic acid+iron, there was some evidence of an increase in insulin resistance, although the P-value for interaction was not significant. Our results on low maternal vitamin B-12 status are in concordance with what was previously reported from a similar population in Pune, India (1) . In that study, children who were born to women in the lowest quartile of the vitamin B-12 distribution at 18 wk of gestation had a 28% increase (P = 0.04) in HOMA-IR at 6 y of age compared to those in the highest quartile. In addition, children in Pune whose mothers had an erythrocyte folate concentration in the upper quartile at 28 wk gestation had a 63% increase in HOMA-IR (P , 0.001). There was some suggestion of an additive effect, where children whose mothers were in the lowest tertile of vitamin B-12 and highest tertile of folate had the highest HOMA-IR, although the P-interaction was not significant (P = 0.7). Using a different measure of folate status (plasma folate) at both early and late pregnancy, we were not able to detect an association with offspring insulin resistance in our study population using either continuous models or dichotomous models with a median cutoff value for folate concentrations. Nor did we find evidence of an interaction between maternal folate and vitamin B-12 status on offspring insulin resistance. The Pune study raised concerns that added folate in the form of supplements or fortified foods to women who have low vitamin B-12 status during pregnancy may have adverse effects on the health of her offspring (2, 3, 22) . In our study population, with a 27% prevalence of vitamin B-12 deficiency, we found no adverse effects of folic acid supplementation on insulin resistance among children born to mothers with low gestational vitamin B-12 status. Plasma folate was within the normal range for 86% of women; only 11 and 3% had low or high folate concentrations at baseline, respectively. Because few of the mothers were beyond these traditional cutoff values, we chose to analyze the data using a median value cutoff. It is possible, however, that an interaction between folate and vitamin B-12 status would become apparent only beyond a certain threshold level that we were unable to examine in this cohort.
We can only speculate on the mechanisms that might link low maternal vitamin B-12 status to offspring insulin resistance. Vitamin B-12 is a necessary cofactor in the methionine synthase reaction, which converts homocysteine into methionine. Thus, low vitamin B-12 nutriture could elevate tissue homocysteine, reflected in plasma, which may lead to poor vascular outcomes in pregnancy, such as preeclampsia, spontaneous abortion, abruption placentae, intrauterine growth restriction, and preterm birth (8) . Methionine is subsequently converted into S-adenosyl methionine, a ubiquitous 1-carbon donor to numerous methylation reactions, including DNA methylation. A reduction in this important methyl donor may have caused epigenetic modifications that contributed to elevation in insulin resistance, as has been suggested in animal models (23, 24) . We would have expected provision of vitamin B-12 contained in the multiple micronutrient supplement to have reversed some of the adverse effects of deficiency. One reason we may not have observed an effect of supplementation is that the amount of vitamin B-12 provided was insufficient to eliminate deficiency in this population of women. We previously reported that from baseline through the 3rd trimester, women who received the multiple micronutrient supplements experienced a mean increase in plasma vitamin B-12 of 50 pmol/L, whereas women in the control group experienced a 114 pmol/L reduction (12) . The prevalence of vitamin B-12 deficiency was significantly reduced by 35% over this period among mothers receiving the multiple micronutrient supplement but was not fully eliminated. Despite this improved status in vitamin B-12, along with corresponding reductions in folate deficiency, there was no change in plasma homocysteine or in the prevalence of hyperhomocysteinemia (.12 mmol/L) during pregnancy with supplementation. A second explanation is that women may have begun supplementation too late in pregnancy, beyond a critical window during which the developing embryo is most sensitive to deficiency. It is unknown whether there is a critical window for the development of insulin resistance. Our intervention began early in pregnancy at a median gestational age of roughly 10 wk of gestation, although it is possible that vitamin B-12 adequacy might be most important closer to the time of conception, when early DNA methylation is rapidly occurring (25) .
Although large, the sample size of our study may have nonetheless been inadequate to detect changes in insulin resistance that could be expected in an undernourished population of children 6-8 y of age. Although we were missing data from 30% of eligible children who did not provide a fasting follow-up blood sample for analysis, these were comparably distributed across treatment groups; therefore, these losses were unlikely to bias our results. We conducted this analysis among children for whom we have collected comprehensive data on micronutrient status of mothers during pregnancy. This subsample of women from the main antenatal supplementation trial was recruited from geographic areas that were more accessible but also balanced the ethnic composition of the rest of the study area. Although socioeconomic patterns in these areas were somewhat different than in the rest of the study area, with greater access to markets and services, our results are likely generalizable to rural populations in the region, where maternal and child undernutrition persist, but where the nutrition transition is likely to emerge, increasing future risk of chronic disease. Among our study's strengths are its biochemical multinutrient profiles assessed at the outset of pregnancy that have allowed us to examine possible differential effects of supplementation by maternal baseline status. Our study presents unique data from a cohort of children born to mothers who participated with high compliance in a randomized, controlled supplementation trial during pregnancy and the early postpartum period, providing a basis for causal inference when examining differences in health effects among offspring that may be observed across maternal supplement groups.
This study supports previous findings that low vitamin B-12 status during pregnancy is associated with an increased risk of insulin resistance in offspring by early school age. In contrast to earlier observations, however, we did not find an association with maternal folate status. We also found no consistent effect of maternal supplementation with folic acid on this outcome. In conclusion, although there was a significant increase in insulin resistance among children whose mothers were vitamin B-12 deficient during pregnancy, we found no evidence of an adverse effect of daily supplementation with 400 mg of folic acid during pregnancy on childhood insulin resistance in this group. 
